NUREXONE BIOLOGIC INC (NRX.CA) Fundamental Analysis & Valuation

TSX-V:NRX • CA67059R1091

Current stock price

0.62 CAD
+0.03 (+5.08%)
Last:

This NRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NRX.CA Profitability Analysis

1.1 Basic Checks

  • NRX had negative earnings in the past year.
  • NRX had a negative operating cash flow in the past year.
  • In the past 5 years NRX always reported negative net income.
  • In the past 5 years NRX always reported negative operating cash flow.
NRX.CA Yearly Net Income VS EBIT VS OCF VS FCFNRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • NRX's Return On Assets of -246.98% is on the low side compared to the rest of the industry. NRX is outperformed by 60.87% of its industry peers.
  • NRX has a Return On Equity (-448.52%) which is in line with its industry peers.
Industry RankSector Rank
ROA -246.98%
ROE -448.52%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRX.CA Yearly ROA, ROE, ROICNRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • NRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NRX.CA Yearly Profit, Operating, Gross MarginsNRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NRX.CA Health Analysis

2.1 Basic Checks

  • NRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NRX.CA Yearly Shares OutstandingNRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
NRX.CA Yearly Total Debt VS Total AssetsNRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M

2.2 Solvency

  • NRX has an Altman-Z score of 0.96. This is a bad value and indicates that NRX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NRX (0.96) is better than 73.91% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that NRX is not too dependend on debt financing.
  • The Debt to Equity ratio of NRX (0.05) is better than 69.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 0.96
ROIC/WACCN/A
WACCN/A
NRX.CA Yearly LT Debt VS Equity VS FCFNRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

  • NRX has a Current Ratio of 1.33. This is a normal value and indicates that NRX is financially healthy and should not expect problems in meeting its short term obligations.
  • NRX has a Current ratio (1.33) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.33 indicates that NRX should not have too much problems paying its short term obligations.
  • NRX's Quick ratio of 1.33 is fine compared to the rest of the industry. NRX outperforms 60.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 1.33
NRX.CA Yearly Current Assets VS Current LiabilitesNRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NRX.CA Growth Analysis

3.1 Past

  • The earnings per share for NRX have decreased strongly by -20.30% in the last year.
EPS 1Y (TTM)-20.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • NRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.80% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25%
EPS Next 2Y11.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NRX.CA Yearly EPS VS EstimatesNRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.02 -0.04 -0.06 -0.08 -0.1

More info and screens

Find the best growth stocksShow best growing peers

0

4. NRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • NRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRX.CA Price Earnings VS Forward Price EarningsNRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRX.CA Per share dataNRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NRX.CA Dividend Analysis

5.1 Amount

  • No dividends for NRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NRX.CA Fundamentals: All Metrics, Ratios and Statistics

NUREXONE BIOLOGIC INC

TSX-V:NRX (3/17/2026, 7:00:00 PM)

0.62

+0.03 (+5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-26
Earnings (Next)03-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.02%
Ins Owner ChangeN/A
Market Cap56.27M
Revenue(TTM)N/A
Net Income(TTM)-6.54M
Analysts84.44
Price Target3.57 (475.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.8%
Min EPS beat(2)-16.5%
Max EPS beat(2)2.91%
EPS beat(4)1
Avg EPS beat(4)-10.44%
Min EPS beat(4)-16.5%
Max EPS beat(4)2.91%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 28.18
P/tB 28.18
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -246.98%
ROE -448.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 1.33
Altman-Z 0.96
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)664.61%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-25%
EPS Next 2Y11.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-254.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-260.23%
OCF growth 3YN/A
OCF growth 5YN/A

NUREXONE BIOLOGIC INC / NRX.CA Fundamental Analysis FAQ

What is the fundamental rating for NRX stock?

ChartMill assigns a fundamental rating of 1 / 10 to NRX.CA.


What is the valuation status of NUREXONE BIOLOGIC INC (NRX.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to NUREXONE BIOLOGIC INC (NRX.CA). This can be considered as Overvalued.


What is the profitability of NRX stock?

NUREXONE BIOLOGIC INC (NRX.CA) has a profitability rating of 0 / 10.


Can you provide the financial health for NRX stock?

The financial health rating of NUREXONE BIOLOGIC INC (NRX.CA) is 3 / 10.